DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Raised to $14.00 at Robert W. Baird

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price boosted by Robert W. Baird from $12.00 to $14.00 in a research report report published on Friday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical instruments supplier’s stock.

Other research analysts have also issued research reports about the company. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their price target for the company from $13.00 to $17.00 in a research report on Thursday, February 19th. Barrington Research reaffirmed an “outperform” rating and set a $14.00 target price on shares of DENTSPLY SIRONA in a report on Monday, January 5th. Mizuho increased their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Stifel Nicolaus set a $13.00 price objective on DENTSPLY SIRONA in a research report on Thursday, November 6th. Finally, Barclays assumed coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They issued an “underweight” rating and a $12.00 target price for the company. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA currently has a consensus rating of “Hold” and a consensus target price of $14.00.

DENTSPLY SIRONA Stock Up 15.5%

Shares of NASDAQ:XRAY opened at $14.68 on Friday. The business has a fifty day moving average price of $12.42 and a two-hundred day moving average price of $12.49. The company has a debt-to-equity ratio of 1.36, a current ratio of 1.47 and a quick ratio of 0.99. The company has a market capitalization of $2.93 billion, a PE ratio of -4.89, a price-to-earnings-growth ratio of 0.99 and a beta of 1.01. DENTSPLY SIRONA has a 1 year low of $9.85 and a 1 year high of $17.34.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 17.62%. The company had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. During the same period in the prior year, the company earned $0.26 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 4.4%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio is currently -14.48%.

Insider Activity

In other DENTSPLY SIRONA news, Director Gregory T. Lucier sold 82,200 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several large investors have recently modified their holdings of the business. Daiwa Securities Group Inc. boosted its stake in DENTSPLY SIRONA by 2.9% during the fourth quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock worth $306,000 after buying an additional 767 shares during the period. Arizona State Retirement System grew its position in DENTSPLY SIRONA by 1.4% in the 3rd quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock valued at $748,000 after acquiring an additional 807 shares in the last quarter. True Wealth Design LLC boosted its stake in shares of DENTSPLY SIRONA by 49.7% in the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 1,181 shares during the period. Sivia Capital Partners LLC grew its holdings in shares of DENTSPLY SIRONA by 5.3% in the third quarter. Sivia Capital Partners LLC now owns 25,774 shares of the medical instruments supplier’s stock valued at $327,000 after purchasing an additional 1,293 shares in the last quarter. Finally, Empowered Funds LLC increased its stake in DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 1,320 shares during the period. Institutional investors and hedge funds own 95.70% of the company’s stock.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.